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ABSTRACT 
The current review article focuses on “Psoriasis”, a form of over-active wound healing response, relatively common, chronic, inflammatory and 
hypersensitive disease of unsolved pathogenesis affecting skin and joints in 2-3% of the general population. Psoriasis is a skin disease driven by immune 
system which starts below the skin's surface and cause severe pain and adverse mental health effects. Genetic susceptibility as well as environmental 
factors plays an important role in determining the development and prognosis of psoriasis.   
Natural Killer (NK) cells are lymphocytes that are best known for killing virally infected and cancer cells. However, evidence is emerging to support a role 
for NK cells in psoriasis. NK cells are found in the inflammatory infiltrate in psoriatic skin lesions. They can produce a range of inflammatory cytokines, 
many of which are important in the pathogenesis of psoriasis. Elucidation of the Immunopathogenesis of psoriasis has led to the discovery of novel 
biologic agents for the treatment of moderate to-severe plaque psoriasis. There are countless therapies currently in the research pipeline, with 
mechanisms ranging from receptor antagonism to signal transduction pathway inhibition. 
Keywords: Pathogenicity, Immune perspectives, Differential Diagnosis, Therapy 
INTRODUCTION 
Psoriasis is chronic inflammatory condition of the skin with significant 
morbidity, affecting approximately 2% of the Caucasian population.1 
Psoriasis comprises red, scaly patches of skin, which usually have very 
well defined edges, appear covered by silvery flaky surface.2 The 
redness is explained by impressive growth and dilation of superficial 
blood vessels.3 They most often occur on the elbows, knees, other parts 
of legs, scalp, lower back, face, palms, and soles of the feet, but they can 
occur on skin anywhere on the body.4 The disease may also affect the 
fingernails, the toenails, and the soft tissues of the genitals and inside 
the mouth.5 
Recent scientific advances have highlighted the role of the immune 
system in psoriasis.6, 7 Activation of memory T-cells is important for 
immune system to generate. Activated T-cells release cytokines, which 
signal accelerated epidermal cell turnover and the keratinocytes and 
vascular changes seen in psoriasis.8 
Psoriasis is sometime associated with arthritis, myopathy, 
enteropathy, spondylitic heart disease or the AIDS.9 Psoriasis is a 
lifelong immune-mediated disease affecting approximately 1.5% of the 
world’s population and is characterized by periods of exacerbations 
and remission. Of the 3 to 5 million people in the United States who are 
affected by psoriasis, approximately 20% to 25% have extensive 
disease requiring aggressive therapy.10, 11, 12 The impact of psoriasis on 
physical and emotional functioning is as great as that of many other 
serious medical conditions, such as canceu`r, heart disease, and 
Crohn’s disease.13 As many as 25% of patients with psoriasis have 
suicidal death because of their disease.14 
About one quarter of patients with Psoriasis (Pso) also develop 






Pso and more so with PsA.16 This may explain why the severity and 
progression of skin, joint, and nail symptoms are frequently 
asynchronous, 17 with joint disease in most of the patients developing 
up to 10 years after the initial skin presentation. Psoriasis does not 
affect skin and joints only. It is a multisystem disease associated with a 
multitude of comorbidities and thus psoriasis has become  increasingly 
important for all medical fields, beyond just dermatology and 
rheumatology. Psoriasis patients show an increased risk for 
cardiovascular events.18, 19 The prevalence of metabolic syndrome – a 
combination of obesity, dyslipidemia, impaired glucose regulation, and 
hypertension – is elevated in psoriasis patients.20 The prevalence of 
depression is increased, and psoriasis can have a substantial psycho-
logical impact on patients.21, 22 
ROLE OF NATURAL KILLER (NK) CELLS IN PSORIASIS 
In addition to cell surface receptors, various molecules are important 
in NK cell functions. The given figure below (Fig 1) shows that NK cells 
can interact with keratinocytes through a range of cell surface 
receptors. NK cells express cell surface receptors that regulate their 
interactions with other cell types including keratinocytes. Among these 
receptors is the NKG2A/CD94 inhibitory receptor that recognises and 
binds to HLA-E on target cells. NK cells also express a number of 
activating receptors including NKG2D which recognises MICA/B stress 
antigen and the Fas receptor which can activate cytokine secretion by 
NK cells. The activating KIR receptor 2DS1 (and its inhibitory 
counterpart, 2DL1) binds the HLA-Cw6 molecule and HLA-Cw6 is the 
strongest genetic association known in psoriasis. There is evidence in 
the literature to suggest that these receptors play a role in psoriasis. 
Activated NK cells are triggered to release their cytotoxic granule 
contents which contain perforin and granzymes.23 
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FIGURE.1 Interaction of NK cells with Keratinocytes through 
range of cell surface receptors (Courtesy: Sinead and Clair 23) 
In one study, perforin, a pore-forming protein found in the cytotoxic 
granules of NK cells and a key mediator of cytotoxicity, was expressed 
at higher levels in the lesional psoriatic skin relative to uninvolved 
psoriatic or healthy control skin.24 Psoriasis patients also had higher 
levels of perforin in their peripheral blood lymphocytes compared to 
healthy controls. However, the source of this perforin does not seem to 
be circulating NK cells, as no difference between the number of 
CD56+Perforin+ or CD16+Perforin+ cells was observed in psoriasis 
patients compared to controls 25; it seems likely that CTLs are 
responsible for the elevated perforin levels. Another study26 has given 
evidence for a role of NK cell-produced perforin in psoriasis, with a 
significantly higher percentage of CD56+Perforin+ found in the 
peripheral blood of patients with severe disease versus those with 
mild psoriasis, but interestingly this difference was not observed 
comparing individuals with severe psoriasis to healthy controls. It was 
also noted that the vast majority of blood cells expressing CD16 were 
also positive for perforin in those with severe disease while a 
significantly lower frequency of CD16 positive cells co-expressing 
perforin was found in patients with mild psoriasis. Cells expressing 
granzyme B, a serine protease that is released from NK cell granules 
and that triggers DNA degradation in target cells, have also been found 
in significantly higher numbers in involved psoriatic skin compared to 
uninvolved psoriatic and healthy skin.24 
TYPES AND PATHOGENICITY OF PSORIASIS 
There are several specific subtypes of psoriasis. The most common 
type of psoriasis, affecting more than 90% of patients, is chronic 
plaque psoriasis or psoriasis vulgaris.11 Other types of psoriasis 
include guttate, erythrodermic, and pustular psoriasis.10,11 Psoriatic 
arthritis is seen in approximately 30% of patients with psoriasis and, if 
left untreated, can cause significant joint damage.11,22 
Psoriasis guttate occurs in about 10% of patients8 and displays small, 
scattered plaques.27,28 This form may develop into psoriasis vulgaris.28 
Pustular psoriasis is an uncommon form of the disease consisting of 
raised pus-filled bumps and large areas of reddened skin.28 A 
proportion of psoriasis patients will develop psoriatic arthritis (PsA), a 
debilitating joint disease.8,27,28 
The cause of psoriasis is still unknown although it is clear that there is 
a strong genetic component to the disease. Several immune genes have 
been associated with psoriasis with the major histocompatibility 
complex on chromosome 6 being strongly implicated.29, 30 Outbreaks of 
psoriasis can occur at sites of physical trauma and streptococcal 
infections have been particularly linked to psoriasis guttate, perhaps 
indicating a role for molecular mimicry.28 There is some evidence that 
psoriasis may be an autoimmune disease; it shares many 
characteristics with multiple sclerosis and diabetes mellitus type 1,31, 32 
but as yet no autoantigens or self-reactive T-cells have been 
identified.30,33 
Biological evidence also supports a physiological differentiation. For 
example, selected key immune mediators of disease in the skin and 
joints differ. Pathologic events in the skin are mediated by autoreactive 
T cells,1 whereas cells in the affected synovium of PsA patients do not 
exhibit the same type of autoreactivity.34 Skin and joint symptoms 
frequently do not respond equally or in parallel to systemic or biologic 
therapeutic agents.35 
Psoriasis vulgaris, the common form of psoriasis, is characterized by 
red, scaly, raised plaques. Although psoriasis vulgaris can occur in 
children, it often begins in late adolescence or early adulthood and 
then usually persists for life. Classic psoriasis vulgaris has a 
predilection for certain areas such as elbows, knees and the scalp. It 
may remain localized or become generalized over time. There are 
clinical variants of psoriasis, defined as subsets, with identical 
histopathological changes in the skin. Guttate psoriasis is characterized 
by small, scattered papules and is potentially linked to preceding 
streptococcal infections.36 other recently described variants of 
psoriasis vulgaris include thick versus thin plaque disease, 37 and small 
versus large plaque disease.38 A notable subset of patients with 
psoriasis develops psoriatic arthritis, a potentially debilitating illness.8  
Psoriasis is essentially a disease of Caucasians, in whom its frequency 
is 1–2%. It is less common in Asians (about 0.1%) and is rarely seen in 
Africans.30 That psoriasis has a genetic basis has been accepted for 
many years30 and it is commonly thought of as a complex trait. So far, 
between 10 and 20 chromosome regions have been proposed to 
harbour psoriasis genes but less than a handful of genes have been 
identified.29, 30 One locus consistently identified in studies of psoriasis 
is the class I region of the major histocompatibility locus antigen 
cluster (MHC).30 However, its low penetrance — about 10% — 
indicates that other genetic and environmental factors are also 
involved.39 The identity of psoriasis susceptibility 1 (PSORS1) remains 
controversial. Although its association with human leukocyte antigen 
(HLA) Cw6 and psoriasis was reported more than 25 years ago, 40 the 
extensive linkage disequilibrium across the class I region and its 
complex evolutionary history has made identification of the 
susceptibility variant(s) very difficult. 
Some genetic variants such as those from the epidermal differentiation 
complex (EDC) might directly affect keratinocyte proliferation or 
differentiation.30 How subtle alterations in keratinocytes 
differentiation interact with alterations in the immune system to lead 
to the development of an inflammatory skin disease will be an 
important area of research as genetics progresses to global association 
scans, attempting to identify most of the common alleles. 
It is important to understand that human skin does a complex organ 
comprise many distinct tissues, and that its structure is significantly 
different from the skin of lower species. Compared with fur-bearing 
animals, human skin has broad areas of epidermis situated between 
hair follicles, known as interfollicular epidermis. There are many 
different skin diseases that involve altered growth of epidermal 
keratinocytes and inflammation in the interfollicular epidermis, and 
psoriasis and atopic eczema are common examples. These disorders do 
not appreciably alter the growth of keratinocytes in the follicular 
epithelium or the growth of hair. Other diseases can alter the growth of 
follicular epithelium, sebaceous glands or hair (the pilosebaceous 
unit), and many such conditions are associated with immune infiltrates 
in or around follicular structures. Psoriasis does not exist as a 
spontaneous disease in the skin of lower animals41 but some features 
of psoriasis have been induced in murine skin by genetic or immune 
manipulations. Even so, the structure of murine skin imposes serious 
limitations on resultant cellular alterations and, so far, psoriasis has 
not been faithfully reproduced by manipulation of native skin in any 
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lower species. The relationship between psoriasis and HIV-1 is also 
interesting because of the clinical observation that HIV-1 infection can 
exacerbate existing psoriasis or trigger new-onset psoriasis.42 As HIV-1 
infection progresses and CD4+ T cell counts decrease, psoriasis can 
worsen.43, 44 This has puzzled dermatologists and infectious disease 
clinicians because it has been convincingly established that psoriasis is 
an immune disorder that is mediated through activation of T cells. 
Several explanations for this ‘‘psoriasis HIV-1 paradox’’ have been 
proposed, including sHIV- 1 induced destruction of regulatory CD4+ T 
cells,45 an increase  in number of memory CD8+ T cells late in disease,46 
HIV 1 proteins acting as super antigens,47 or co-stimulation through 
traditional antigenic presentation.45 
THE IMMUNE PERSPECTIVE 
There is a plethora of studies supporting the view that dysregulation of 
the immune system is central in psoriasis pathogenesis, particularly 
through T-cell-dependent mechanisms. Therapeutic efficacy of 
pharmaceuticals like cyclosporine, which inhibit the production of 
cytokines involved in T-cell activation, demonstrated the importance of 
immunity in psoriasis pathogenesis.48 More recently, antibodies 
against specific T-cell-bound activating molecules like CD2 and CD11a 
indicated a more specific role for T-cells.49 Moreover, healthy 
individuals transplanted with bone marrow from donors with 
psoriasis can develop the disease, while psoriasis patients receiving 
bone marrow from a healthy donor can clinically improve.50, 51 
Immunocytes present in human psoriasis skin engrafted on to different 
immunodeficient mice induce signs of disease. 
Distinctive patterns of cell infiltration occur in lesional psoriasis skin; 
CD8+ T cells as well as neutrophils target the epidermis, the latter 
forming microabscesses that contain large amounts of cellular debris. 
Dendritic (DC) and CD4+ T-cells tend to accumulate in the 
interpapillary dermis. Large immune cell conglomerates can be found 
in deeper dermal locations, reminiscent of lymphoid tissues 
elsewhere.52 The majority of T-cells in psoriasis lesions are activated 
memory cells expressing co-stimulatory molecules and the cutaneous 
lymphocyte-associated antigen, CLA. The mode of cooperation 
between different cell types in psoriasis is under exploration, but it is 
clear that T-cell and DC interaction is necessary for disease to occur. 
Several DC types are found in psoriatic skin besides resident 
Langerhan’s cells, such as immature dermal DCs and plasmacytoid DCs. 
Of these, plasmacytoid DCs may be of particular significance in 
psoriasis pathogenesis due to their ability to produce large amounts of 
IFN-α.53 Psoriasis is considered a Th1-driven disease as opposed to 
atopic dermatitis which is regarded as Th2-regulated based on the 
cytokine patterns produced in the respective lesions.54 
DIFFERENTIAL DIAGNOSIS 
The differential diagnosis of psoriasis is vast and depends on the 
clinical subtype. Chronic plaque psoriasis must be distinguished from 
the mycosis fungoides variant of cutaneous T-cell lymphoma (CTCL). 
The latter often exhibits signs of epidermal atrophy or poikiloderma 
which allow its differentiation from plaque psoriasis; however, 
occasionally, a skin biopsy is the only way to distinguish between the 
two. Pityriasis rubra pilaris (PRP) is clinically distinguished from 
plaque psoriasis by the presence of red-orange palmoplantar 
keratoderma, keratotic follicular papules, and the classic islands of 
sparing on the trunk. Histopathologically, the alternating vertical and 
horizontal ortho- and parakeratosis as well as follicular plugging help 
distinguish PRP from psoriasis. Nummular dermatitis and Bowen’s 
disease are also in the differential diagnosis of plaque psoriasis. 
Nummular dermatitis is more pruritic than psoriasis and is often 
associated with a history of atopy. Histopathological examination is the 
most reliable way to differentiate between a plaque of psoriasis and 
Bowen’s disease.  
When psoriasis involves the shins, a diagnosis of hypertrophic lichen 
planus may be entertained, but typical lichen planus lesions elsewhere 
on the body as well as mucosal involvement may help to differentiate 
between the two. Guttate psoriasis is often straightforward to 
diagnose; however, the clinical differential diagnosis includes small 
plaque parapsoriasis, pityriasis rosea, pityriasis lichenoides chronica 
(PLC), and secondary syphilis. These entities can be distinguished on 
the basis of key historical, clinical, pathologic, and laboratory findings. 
Small plaque parapsoriasis usually presents with variably 
erythematous plaques which are covered with fine scale. Occasionally, 
it may present with elongated, finger-like patches symmetrically 
distributed on the flanks, also known as “digitate dermatosis.” 
Pityriasis rosea is distinguished from psoriasis by the presence of a 
herald patch and resolution of the lesions within a few months. 
Secondary syphilis may be clinically distinguished on the basis of 
palmoplantar involvement, which does not happen in guttate psoriasis, 
as well as on the basis of histopathologic and serologic findings. PLC is 
clinically characterized by recurrent crops of spontaneously 
regressing, scaly red-brown papules.  
Histologically, there is an interface dermatitis composed 
predominantly of monoclonal T-lymphocytes and necrotic 
keratinocytes. Pustular psoriasis may resemble a pustular drug 
reaction, such as acute generalized exanthematous pustulosis (AGEP), 
Sneddon–Wilkinson disease, or IgA pemphigus. The presence of 
peripheral eosinophilia and tissue eosinophils on the skin biopsy, as 
well as a history of a preceding culprit medication favors AGEP. 
Sneddon–Wilkinson disease can be distinguished clinically by its 
annular or polycyclic plaques with a predilection for flexural surfaces. 
The diagnosis of IgA pemphigus is made via positive direct 
immunofluorescence, which is absent in both psoriasis and Sneddon–
Wilkinson disease. The annular form of pustular psoriasis may also 
mimic Sneddon–Wilkinson disease. The principal differential 
diagnostic considerations of flexural psoriasis include intertrigo and 
Langerhans cell histiocytosis in infants.  
Patients with Langerhans cell histiocytosis may have scaling and 
crusting of the scalp, as well as internal organ involvement (eg, 
hepatomegaly, lytic bone lesions). A skin biopsy is diagnostic. The 
differential diagnoses for palmoplantar psoriasis include dyshidrotic 
dermatitis and tinea manuum/pedum. Yellow-brown macules 
intermixed with sterile pustules favor a diagnosis of palmoplantar 
psoriasis. KOH examination of the associated scale can help diagnose a 
dermatophyte infection. Nail psoriasis may mimic alopecia areata, 
lichen planus, or trachyonychia. Nail pitting is a feature of both 
psoriasis and alopecia areata; however, pits are large, deep and 
irregularly distributed in psoriasis in contrast to alopecia areata, 
where they are small, superficial, and regularly distributed. Oil drops, 
distal onycholysis, and splinter hemorrhages may also serve to 
distinguish between the two entities. 
 Lateral nail thinning, longitudinal ridging, fissuring, and dorsal 
pterygium are features which favor lichen planus. Trachyonychia, or 
twenty-nail dystrophy, may be due to alopecia areata, lichen planus, or 
psoriasis. In the absence of cutaneous findings, a nail unit biopsy may 
help establish the underlying cause. Scalp psoriasis may resemble tinea 
capitis or seborrheic dermatitis. While psoriasis can often be clinically 
differentiated from tinea capitis, laboratory testing is sometimes 
necessary to establish the diagnosis of a dermatophyte infection. This 
includes a KOH preparation, a fungal culture, or microscopic 
examination of a skin biopsy specimen. Seborrheic dermatitis and 
psoriasis may present clinically very similarly and often respond to the 
same topical treatment. The presence of psoriatic plaques on the trunk 
as well as a positive family history may favor psoriasis.  
Histopathological examination remains the standard of differentiating 
between the two. Finally, erythrodermic psoriasis has a vast 
differential, as there are many other causes of erythroderma including 
seborrheic dermatitis, atopic dermatitis, Sezary syndrome, PRP, drug 
reactions, and graft-versus-host disease. A skin biopsy may or may not 
establish the underlying cause. Often, psoriatic erythroderma is 
preceded by classic psoriatic plaques; however, typical features of 
psoriasis are lost after generalization of the erythema. Nail changes, 
such as nail pitting, oil drops, or onycholysis may still be visible and 
provide a clue to the diagnosis of psoriatic erythroderma.55 
CONVENTIONAL THERAPY 
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Approximately 80% of the psoriatic population has mild-to-moderate 
disease (localized cutaneous manifestations; body surface area # 10%) 
of which the majority can be successfully managed with topical agents 
such as corticosteroids, vitamin D3 analogs, vitamin A derivatives, 
emollients, keratolytics, and/or coal tar.56, 57 Moderate-to-severe 
disease with more widespread cutaneous manifestations (body surface 
area. 10%) and/or nail or joint disease may require phototherapy 
(ultraviolet B or ultra violet a radiation) with psoralen, known as 
photochemotherapy, or systemic agents.58 Conventional systemic 
therapies such as MTX, CSA and acitretin can be used in the long term, 
but often have limitations due to more severe side effects (organ 
toxicity, skin cancer), lack of sustainable efficacy, and inconvenient 
administration schedules.59, 60 
TRADITIONAL THERAPY 
Even without modern knowledge of psoriasis pathogenesis, patients 
have benefited from the constant improvement of conventional 
therapies. Most of the currently accepted systemic treatments for 
psoriasis were developed empirically or were found by pure chance. 
However, modern knowledge has shed light on the mode of action of 
some of these classic treatments. Fumaric acid and cyclosporine are 
mainly immunosuppressive, retinoids target keratinocytes, and 
methotrexate affects both keratinocytes and immune cells.48, 61, 62, 63 
Even though these therapies continue to play an important role in 
psoriasis treatment, they have not fully met the needs of patients.64 
TARGETED BIOLOGIC THERAPY 
Elucidation of the immunologic circuits in the pathogenesis of psoriasis 
has encouraged the development of novel targeted systemic treatment 
options known as “biologics”. By targeting specific pathways in the 
immunopathogenesis of psoriasis, progression of the disease can be 
interrupted, resulting in both cutaneous and systemic disease 
clearance. In some instances, disease clearance may be complete (eg, 
PASI 100) and long-standing. There are currently five biologic agents 
approved by the US Food and Drug Administration for psoriasis, 
alefacept (Amevive®, Biogen Inc, Cambridge, MA), etanercept 
(Enbrel®, Amgen, Seattle, WA), infliximab (Remicade®, Janssen 
Biotech Inc, Horsham, PA), adalimumab (Humira®, Abbott 
Laboratories, North Chicago, IL), and ustekinumab (Stelara®, Janssen 
Biotech Inc). Newer more targeted agents are in development and in 
clinical trials. Another immunosuppressant inhibiting lymphocyte 
activation and cell migration out of blood vessels into tissues, 
efalizumab (Raptiva®, Genentech, South San Francisco, CA), was taken 
off the market in 2009 when four cases of progressive multifocal 
leukoencephalopathy (John Cunningham virus brain infection) were 
reported in plaque psoriasis patients.65 
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